Catalog No.
YHG06301
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Pro42-Val129
Predicted molecular weight
37.91 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q05940
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
SVMT, VMAT2, Monoamine transporter, Synaptic vesicular amine transporter, VAT2, SLC18A2, Solute carrier family 18 member 2, Vesicular amine transporter 2
Treatment of Tardive Dyskinesia. PMID: 32279716
Genetic Dystonias: Update on Classification and New Genetic Discoveries. PMID: 33564903
Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. PMID: 26905753
Identifying the hub gene and immune infiltration of Parkinson's disease using bioinformatical methods. PMID: 35278479
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. PMID: 19228741
Valbenazine-induced parkinsonism. PMID: 31785443
The psychopharmacology of Huntington disease. PMID: 31727211
Current treatment of tardive dyskinesia. PMID: 30591350
Vesicular monoamine transporter 2 (SLC18A2) regulates monoamine turnover and brain development in zebrafish. PMID: 34403568
SLC18A2 promoter haplotypes and identification of a novel protective factor against alcoholism. PMID: 15829504
High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. PMID: 20181938
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. PMID: 29455579
Brain monoamine vesicular transport disease caused by homozygous SLC18A2 variants: A study in 42 affected individuals. PMID: 36318270
VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. PMID: 30983500
Valbenazine for the treatment of tardive dyskinesia. PMID: 28276538
Genetic variations in the 3'-untranslated region of SLC18A2 are associated with serum FSH concentration in polycystic ovary syndrome patients and regulate gene expression in vitro. PMID: 27354380
How "Neuronal" Are Human Skin Mast Cells? PMID: 36142795
Protein cysteine S-nitrosylation inhibits vesicular uptake of neurotransmitters. PMID: 26541750
Genetic analysis of P387L mutation in SLC18A2 gene in sporadic Parkinson's disease in Chinese Han population. PMID: 26333488
Motility phenotype in a zebrafish vmat2 mutant. PMID: 34986152
Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. PMID: 25746685
Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2. PMID: 30198706
VMAT2 and Parkinson's disease: harnessing the dopamine vesicle. PMID: 25220836
VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). PMID: 29680151
Tetrabenazine (Xenazine) for Huntington's chorea. PMID: 19172140
Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. PMID: 24018103
Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities. PMID: 30847375
Imaging of beta-cell mass and function. PMID: 20554742
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. PMID: 29609698
GPR44 is a pancreatic protein restricted to the human beta cell. PMID: 26467464
Combining CRISPR-Cas9 and brain imaging to study the link from genes to molecules to networks. PMID: 36161926
Dopamine transporters and neuronal injury. PMID: 10498956
Valbenazine (Ingrezza) for tardive dyskinesia. PMID: 28520698
SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. PMID: 23506877
Clinical spectrum of dopa-responsive dystonia and related disorders. PMID: 24844652
Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma. PMID: 31317476
Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease. PMID: 27520881
Presynaptic regulation of dopamine release: Role of the DAT and VMAT2 transporters. PMID: 30465801
Gene therapy for Parkinson's disease. PMID: 15000692
The vesicular monoamine transporter 2: an underexplored pharmacological target. PMID: 24398404
Chronic methylphenidate preferentially alters catecholamine protein targets in the parietal cortex and ventral striatum. PMID: 30660754
Genetic association analysis of 300 genes identifies a risk haplotype in SLC18A2 for post-traumatic stress disorder in two independent samples. PMID: 24525708
Monoamine transporters in human endometrium and decidua. PMID: 18987100
Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. PMID: 21939588
Assignment of the mouse vesicular monoamine transporter genes, Slc18a1 and Slc18a2, to chromosomes 8 and 19 by linkage analysis. PMID: 8661734
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? PMID: 30160230
Association of DNA polymorphisms in the synaptic vesicular amine transporter gene (SLC18A2) with alcohol and nicotine dependence. PMID: 15988470
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. PMID: 29249207
A case report of infantile parkinsonism-dystonia-2 caused by homozygous mutation in the SLC18A2 gene. PMID: 34078222
Pancreatic Differentiation from Murine Embryonic Stem Cells. PMID: 25762295
Pharmacotherapy: Quest for the quitting pill. PMID: 26107096
In vivo beta-cell imaging with VMAT 2 ligands--current state-of-the-art and future perspective. PMID: 20146666
Effect of genetic modifications in the synaptic dopamine clearance systems on addiction-like behaviour in mice. PMID: 21118356
[Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder]. PMID: 21365590
Vesicular monoamine transporter 2: role as a novel target for drug development. PMID: 17233532
Endocannabinoid involvement in endometriosis. PMID: 20833475
Vesicular monoamine transporter 2 mediates fear behavior in mice. PMID: 31898856
Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation. PMID: 20849328
HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. PMID: 22570010
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. PMID: 29667946
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. PMID: 26338179
In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. PMID: 11099458
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. PMID: 14597329
How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care. PMID: 33147658
Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission. PMID: 18199119
Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. PMID: 27836486
Protein kinase A affects trafficking of the vesicular monoamine transporters in PC12 cells. PMID: 15522101
Chromogranin A and vesicular monoamine transporter 2 immunolocalization in protein bodies of human locus coeruleus neurons. PMID: 23573890
Are striatal tyrosine hydroxylase interneurons dopaminergic? PMID: 25904808
Restoration of Noradrenergic Function in Parkinson's Disease Model Mice. PMID: 33940943
Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors. PMID: 30954278
Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters. PMID: 33378168
U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells. PMID: 28407359
Connectivity adaptations in dopaminergic systems define the brain maturity of investors. PMID: 34083626
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. PMID: 21522164
Co-expression studies of the orphan carrier protein Slc10a4 and the vesicular carriers VAChT and VMAT2 in the rat central and peripheral nervous system. PMID: 21742018
Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules. PMID: 7823026
Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. PMID: 12505801
Ephedrine decreases vesicular monoamine transporter-2 function. PMID: 21370280
Cocaine increases dopaminergic connectivity in the nucleus accumbens. PMID: 29027032
The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. PMID: 11099463
Imaging the vesicular monoamine transporter. PMID: 11553983
Electron microscopic immunolabeling of transporters and receptors identifies transmitter-specific functional sites envisioned in Cajal's neuron. PMID: 12143378
hVMAT2: A Target of Individualized Medication for Parkinson's Disease. PMID: 27137201
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. PMID: 32084491
Fenpropathrin, a Widely Used Pesticide, Causes Dopaminergic Degeneration. PMID: 25575680
VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder. PMID: 34758845
Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. PMID: 10192785
Changing distribution of monoaminergic markers in the developing human cerebral cortex with special emphasis on the serotonin transporter. PMID: 11997877
A study of the age-related effects of lactational atrazine exposure. PMID: 28341570
Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice. PMID: 36257461
The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. PMID: 12827358
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. PMID: 30240563
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. PMID: 28489481
Mir-421 and mir-550a-1 are potential prognostic markers in esophageal adenocarcinoma. PMID: 36829221
Brain dopamine-serotonin vesicular transport disease and its treatment. PMID: 23363473
For research use only. Not for human or drug use.
